About a quarter of people risk heart attacks and strokes because they inherited a kind of cholesterol that statin drugs can’t ...

This stands to reason, as nearly every stage of drug development and marketing is resource- and capital-intensive, and as a ...

The US giants which supply vital new medicines to UK patients face disruption from Donald Trump’s trade barriers, experts warn ...

Leading pharmacy benefit managers are shifting away from lucractive rebates on biologic drugs and toward lower-cost ...

A large database study suggests that patients with primary dysautonomias face a significantly increased risk for seborrheic ...

Angina Pectoris Drugs Market Size and ForecastThe global angina pectoris drugs market is poised for substantial growth over ...

Bkemv is being offered at 10% off Soliris, and Epysqli is offered at 30% below Soliris. Both biosimilars treat several of the ...

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Throughout the 1990s, Amgen continued in the same vein, investing heavily in R&amp,D, expanding its sales and bringing out new medications such as Infergen, an anti-hepatitis C medication ...

An In-depth Market Research ReportThe Cancer Biologics Market is one of the fastest-growing segments within the global ...